Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;2(1):298-313.
doi: 10.3390/v2010298. Epub 2010 Jan 22.

Dual Role of p53 in Innate Antiviral Immunity

Carmen Rivas  1 , Stuart A Aaronson  2 , Cesar Munoz-Fontela  2
Affiliations

Dual Role of p53 in Innate Antiviral Immunity

Carmen Rivas et al. Viruses. 2010 Jan.

Abstract

Tumor suppressor p53 is widely known as 'the guardian of the genome' due to its ability to prevent the emergence of transformed cells by the induction of cell cycle arrest and apoptosis. However, recent studies indicate that p53 is also a direct transcriptional target of type I interferons (IFNs) and thus, it is activated by these cytokines upon viral infection. p53 has been shown to contribute to virus-induced apoptosis, therefore dampening the ability of a wide range of viruses to replicate and spread. Interestingly, recent studies also indicate that several IFN-inducible genes such as interferon regulatory factor 9 (IRF9), IRF5, IFN-stimulated gene 15 (ISG15) and toll-like receptor 3 (TLR3) are in fact, p53 direct transcriptional targets. These findings indicate that p53 may play a key role in antiviral innate immunity by both inducing apoptosis in response to viral infection, and enforcing the type I IFN response, and provide a new insight into the evolutionary reasons why many viruses encode p53 antagonistic proteins.

Keywords: apoptosis; immunity; interferon; p53.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic of the activators and effectors of p53-dependent response in antiviral immunity.
See this image and copyright information in PMC

References

    1. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–264. - PubMed
    1. García-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in détente. Science. 2006;312:879–882. - PubMed
    1. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol. 1999;27:1583–1592. - PubMed
    1. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516–523. - PubMed
    1. Muñoz-Fontela C, Garcia MA, Garcia-Cao I, Collado M, Arroyo J, Esteban M, Serrano M, Rivas C. Resistance to viral infection of super p53 mice. Oncogene. 2005;24:3059–3062. - PubMed